{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000027","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.562515+00:00","generated_at":"2026-06-17T02:49:15.870602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"QuidelOrtho pre-announces Q1 revenue $840-850M; non-respiratory grows 5-7%","bullets":["Total preliminary Q1 revenue $840-850M; respiratory $262-267M including COVID-19 $212-217M.","Non-respiratory revenue $578-583M, up ~5% supplemental combined basis (~7% constant currency).","Labs business unit drove growth including ~$21M settlement from a collaboration agreement.","CEO Douglas Bryant says Q1 ahead of expectations; confident in sustainable high-single-digit growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000027","json":"https://secwatch.observer/filing/0001906324-23-000027.json","markdown":"https://secwatch.observer/filing/0001906324-23-000027.md","text":"https://secwatch.observer/filing/0001906324-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000027/0001906324-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000027/qdel-20230413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:49:15.870602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31976de88f063c3189bb949a37fcefb851b1e76d","claim":"QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $840 million to $850 million.","evidence_excerpt":"today announced preliminary revenue results for the first quarter ended April 2, 2023. The Company expects total revenues in the first quarter of 2023 to be in the range of $840 million to $850 million. Respiratory product revenue is expected to be in the range of $262 million to $267 million, including COVID-19 product revenue of $212 million to $217 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000027/0001906324-23-000027-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended April 2, 2023"},{"label":"Revenue","value":"$840 million to $850 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}